







# AKI Gets a Makeover: How Science is Reshaping Treatment Options

The healthcare industry is undergoing rapid change, especially in areas like the [cardiovascular surgery pipeline product market](#) and acute kidney injury (AKI) treatment. With rising incidences of complex cardiovascular procedures and kidney-related complications, companies are ramping up efforts to develop more effective treatments and interventions.

## A Growing Focus on the Acute Kidney Injury Market

The [acute kidney injury market](#) is gaining considerable momentum. AKI, often triggered by major surgeries, infections, or nephrotoxic medications, poses a serious risk to hospitalized patients. New drug candidates and preventive strategies are fueling optimism in this space, with a number of therapies progressing through advanced stages of development.

## Renibus Therapeutics Leads with RBT-1

Renibus Therapeutics is at the forefront with its lead candidate, RBT-1, which is being evaluated for the prevention of AKI following cardiothoracic surgery. By inducing protective and anti-inflammatory effects in the body, the therapy aims to reduce postoperative complications. The potential of [Renibus Heal](#) in high-risk surgical patients underscores a significant shift toward preventive renal care.

## AM-Pharma's Ilofotase Alfa Shows Promise

Biotech firm [Ampharma](#) is developing ilofotase alfa for the treatment of sepsis-induced AKI. This recombinant alkaline phosphatase targets inflammation and endothelial dysfunction, two key drivers of kidney damage in septic patients. Currently in Phase III trials, the therapy has already received regulatory backing with a Fast Track designation.

## RenalGuard: A Technology-Driven AKI Solution

The [Renal Guard](#) system offers a device-based solution to prevent kidney injury during high-risk medical procedures. By actively managing fluid levels and promoting high urine output, it helps prevent contrast-induced nephropathy and AKI during cardiac surgeries, making it a valuable addition to procedural care strategies.

## Market Outlook: Acute Kidney Injury Treatment

With growing investments, regulatory support, and novel approaches in the pipeline, the [acute kidney injury treatment market](#) is projected to experience significant expansion over the coming decade. The introduction of targeted drugs and supportive devices reflects an industry-wide commitment to improving outcomes for patients at risk of kidney complications.

## Teprasiran: A Novel RNA-Based Candidate

Among the more innovative therapies is [Teprasiran](#), an RNA interference drug that targets the p53 gene to prevent cell death after kidney injury. Developed by Quark Pharmaceuticals, teprasiran has shown encouraging results in reducing the incidence and severity of AKI in patients undergoing major cardiovascular procedures, offering hope for a new class of nephroprotective therapies.

Cardio-Renal Innovation at the Crossroads

